Positive News SentimentPositive NewsNASDAQ:HOWL Werewolf Therapeutics (HOWL) Stock Forecast, Price & News $2.84 +0.33 (+13.15%) (As of 05/26/2023 03:59 PM ET) Add Compare Share Share Today's Range$2.55▼$2.9050-Day Range$2.17▼$3.0452-Week Range$1.39▼$7.51Volume37,000 shsAverage Volume203,703 shsMarket Capitalization$101.13 millionP/E RatioN/ADividend YieldN/APrice Target$11.10 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Werewolf Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside290.8% Upside$11.10 Price TargetShort InterestHealthy0.23% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.42) to ($1.81) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.37 out of 5 starsMedical Sector250th out of 1,010 stocksPharmaceutical Preparations Industry105th out of 494 stocks 3.5 Analyst's Opinion Consensus RatingWerewolf Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.10, Werewolf Therapeutics has a forecasted upside of 290.8% from its current price of $2.84.Amount of Analyst CoverageWerewolf Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.23% of the float of Werewolf Therapeutics has been sold short.Short Interest Ratio / Days to CoverWerewolf Therapeutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldWerewolf Therapeutics does not currently pay a dividend.Dividend GrowthWerewolf Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HOWL. Previous Next 3.3 News and Social Media Coverage News SentimentWerewolf Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Werewolf Therapeutics this week, compared to 2 articles on an average week.Search Interest4 people have searched for HOWL on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Werewolf Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders62.70% of the stock of Werewolf Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions68.17% of the stock of Werewolf Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Werewolf Therapeutics are expected to decrease in the coming year, from ($1.42) to ($1.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Werewolf Therapeutics is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Werewolf Therapeutics is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioWerewolf Therapeutics has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Werewolf Therapeutics (NASDAQ:HOWL) StockWerewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.Read More Receive HOWL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Werewolf Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address HOWL Stock News HeadlinesMay 16, 2023 | americanbankingnews.comFinancial Survey: Werewolf Therapeutics (NASDAQ:HOWL) and Onconova Therapeutics (NASDAQ:ONTX)May 16, 2023 | americanbankingnews.comWerewolf Therapeutics (NASDAQ:HOWL) PT Raised to $10.00May 29, 2023 | Stocks To Trade (Ad)Free SMS Trade Alerts. Up to 15 opportunities a day.Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 15, 2023 | markets.businessinsider.comSVB Securities Keeps Their Buy Rating on Werewolf Therapeutics (HOWL)May 13, 2023 | msn.comB of A Securities Maintains Werewolf Therapeutics (HOWL) Buy RecommendationMay 12, 2023 | msn.comHC Wainwright & Co. Reiterates Werewolf Therapeutics (HOWL) Buy RecommendationMay 12, 2023 | markets.businessinsider.comBank of America Securities Keeps Their Buy Rating on Werewolf Therapeutics (HOWL)May 11, 2023 | msn.comRecap: Werewolf Therapeutics Q1 EarningsMay 29, 2023 | Stocks To Trade (Ad)15 A.I. Trading Opportunities a DayUsing our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 11, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Werewolf Therapeutics (HOWL)May 11, 2023 | markets.businessinsider.comExpert Ratings for Werewolf TherapeuticsMay 11, 2023 | finance.yahoo.comWerewolf Therapeutics, Inc. (HOWL) Reports Q1 Loss, Tops Revenue EstimatesMay 11, 2023 | finance.yahoo.comWerewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 1, 2023 | finance.yahoo.comWerewolf Therapeutics to Participate in May Investor ConferencesApril 24, 2023 | news.yahoo.com‘Stunning’ Wolf Discovery Caught On Wildlife Camera In MinnesotaApril 20, 2023 | marketwatch.comWerewolf Therapeutics Publishes Preclinical Data on mWTX-330, an IL-12 INDUKINE(TM) Molecule, in Cancer Immunology ResearchApril 19, 2023 | finanznachrichten.deWerewolf Therapeutics, Inc.: Werewolf Therapeutics Publishes Preclinical Data on mWTX-330, an IL-12 INDUKINE Molecule, in Cancer Immunology ResearchApril 19, 2023 | technews.tmcnet.comWerewolf Therapeutics Publishes Preclinical Data on mWTX-330, an IL-12 INDUKINE™ Molecule, in Cancer Immunology ResearchApril 19, 2023 | finance.yahoo.comWerewolf Therapeutics Publishes Preclinical Data on mWTX-330, an IL-12 INDUKINE™ Molecule, in Cancer Immunology ResearchMarch 29, 2023 | americanbankingnews.comAnalysts Set Expectations for Werewolf Therapeutics, Inc.'s Q1 2023 Earnings (NASDAQ:HOWL)March 28, 2023 | markets.businessinsider.comSVB Securities Sticks to Its Buy Rating for Werewolf Therapeutics (HOWL)March 27, 2023 | americanbankingnews.comWerewolf Therapeutics (NASDAQ:HOWL) Earns Buy Rating from EF Hutton Acquisition Co. IMarch 24, 2023 | msn.comWerewolf Therapeutics Earnings Perspective: Return On Capital EmployedMarch 24, 2023 | markets.businessinsider.comAnalyst Ratings for Werewolf TherapeuticsMarch 24, 2023 | americanbankingnews.comWerewolf Therapeutics (NASDAQ:HOWL) PT Lowered to $15.00March 23, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Buy Rating for Werewolf Therapeutics (HOWL)March 23, 2023 | finance.yahoo.comWerewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Tops Revenue EstimatesSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive HOWL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Werewolf Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address HOWL Company Calendar Last Earnings11/10/2021Today5/29/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HOWL CUSIPN/A CIK1785530 Webwerewolftx.com Phone617-952-0555FaxN/AEmployees39Year FoundedN/APrice Target and Rating Average Stock Price Forecast$11.10 High Stock Price Forecast$15.00 Low Stock Price Forecast$8.30 Forecasted Upside/Downside+290.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-53,810,000.00 Net Margins-241.79% Pretax Margin-241.79% Return on Equity-40.02% Return on Assets-28.70% Debt Debt-to-Equity Ratio0.32 Current Ratio7.21 Quick Ratio7.21 Sales & Book Value Annual Sales$16.40 million Price / Sales6.17 Cash FlowN/A Price / Cash FlowN/A Book Value$3.98 per share Price / Book0.71Miscellaneous Outstanding Shares35,610,000Free Float13,283,000Market Cap$101.13 million OptionableNot Optionable Beta0.20 Key ExecutivesDr. Daniel J. Hicklin Ph.D. (Age 58)Founder, CEO, Pres, Sec. & Director Comp: $762.87kMr. Timothy W. Trost CPA (Age 64)CFO, Treasurer & Assistant Sec. Comp: $511.88kDr. Chulani Karunatilake Ph.D.Chief Technology OfficerDr. Reid Leonard Ph.D. (Age 63)Chief Operating Officer Dr. Cynthia Seidel-Dugan Ph.D. (Age 63)Chief Scientific Officer Dr. Randi Isaacs M.D. (Age 66)Chief Medical Officer Ms. Ellen A. Lubman M.B.A. (Age 46)Chief Bus. Officer More ExecutivesKey CompetitorsSpruce BiosciencesNASDAQ:SPRBLeap TherapeuticsNASDAQ:LPTXTransCode TherapeuticsNASDAQ:RNAZVeruNASDAQ:VERUBriaCell TherapeuticsNASDAQ:BCTXView All CompetitorsInsiders & InstitutionsAlyeska Investment Group L.P.Bought 191,607 shares on 5/16/2023Ownership: 1.120%HBK Sorce Advisory LLCBought 52,908 shares on 5/16/2023Ownership: 0.149%State Street CorpBought 17,800 shares on 5/16/2023Ownership: 0.143%Rubric Capital Management LPBought 99,970 shares on 5/15/2023Ownership: 5.449%Schonfeld Strategic Advisors LLCBought 73,418 shares on 5/15/2023Ownership: 0.207%View All Insider TransactionsView All Institutional Transactions HOWL Stock - Frequently Asked Questions Should I buy or sell Werewolf Therapeutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Werewolf Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HOWL shares. View HOWL analyst ratings or view top-rated stocks. What is Werewolf Therapeutics' stock price forecast for 2023? 2 equities research analysts have issued twelve-month price objectives for Werewolf Therapeutics' stock. Their HOWL share price forecasts range from $8.30 to $15.00. On average, they anticipate the company's stock price to reach $11.10 in the next twelve months. This suggests a possible upside of 290.8% from the stock's current price. View analysts price targets for HOWL or view top-rated stocks among Wall Street analysts. How have HOWL shares performed in 2023? Werewolf Therapeutics' stock was trading at $2.05 at the start of the year. Since then, HOWL shares have increased by 38.5% and is now trading at $2.84. View the best growth stocks for 2023 here. When is Werewolf Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our HOWL earnings forecast. How were Werewolf Therapeutics' earnings last quarter? Werewolf Therapeutics, Inc. (NASDAQ:HOWL) released its earnings results on Wednesday, November, 10th. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.45) by $0.06. Werewolf Therapeutics had a negative net margin of 241.79% and a negative trailing twelve-month return on equity of 40.02%. When did Werewolf Therapeutics IPO? (HOWL) raised $101 million in an initial public offering on Friday, April 30th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, SVB Leerink and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager. What is Werewolf Therapeutics' stock symbol? Werewolf Therapeutics trades on the NASDAQ under the ticker symbol "HOWL." Who are Werewolf Therapeutics' major shareholders? Werewolf Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Rubric Capital Management LP (5.45%), Alyeska Investment Group L.P. (1.12%), Acadian Asset Management LLC (0.22%), Schonfeld Strategic Advisors LLC (0.21%), HBK Sorce Advisory LLC (0.15%) and State Street Corp (0.14%). Insiders that own company stock include Bioventures 2014 LP Mpm, Ra Capital Management, LP and Reid Leonard. View institutional ownership trends. How do I buy shares of Werewolf Therapeutics? Shares of HOWL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Werewolf Therapeutics' stock price today? One share of HOWL stock can currently be purchased for approximately $2.84. How much money does Werewolf Therapeutics make? Werewolf Therapeutics (NASDAQ:HOWL) has a market capitalization of $101.13 million and generates $16.40 million in revenue each year. The company earns $-53,810,000.00 in net income (profit) each year or ($1.66) on an earnings per share basis. How can I contact Werewolf Therapeutics? Werewolf Therapeutics' mailing address is 1030 MASSACHUSETTS AVENUE SUITE 210, CAMBRIDGE MA, 02138. The official website for the company is werewolftx.com. The company can be reached via phone at 617-952-0555 or via email at ir@werewolftx.com. This page (NASDAQ:HOWL) was last updated on 5/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Werewolf Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.